In conclusion, we have developed a SOR@TF-Fe3+ NVs drug, which not only competently induces ferroptosis by acting on two pathways [XC ̄(SLC7A11)/GPX4 and iron ion transport], but also specially targets TFRC highly-expressed HCC cells. This evidence concerns the gene TFRC and hepatocellular carcinoma.